5609.35 180.25 (3.32%)
293.1K NSE+BSE Volume
NSE Sep 29, 2023 12:07 PM
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
24 Aug 2023 | Dr. Reddy's Laborato.. |
Geojit BNP Paribas
|
5609.35 | 6212.00 | 5907.15 (-5.04%) | 10.74 |
Hold
|
||||
28 Jul 2023 | Dr. Reddy's Laborato.. |
KRChoksey
|
5609.35 | 6560.00 | 5583.00 (0.47%) | 16.95 |
Buy
|
Strong quarter; rebound in US prices & gRevlimid drives growth
KRChoksey
DRReddy’s consolidated revenue increased by 7% QoQ to INR 67,579 Mn (+35% YoY ). The company reported a YoY revenue growth, driven increase in North America generics sales, The North America generics revenue stood at USD 390 Mn. The growth in this region was mainly driven by growth in gRevlimid sales.
|
|||
27 Jul 2023 | Dr. Reddy's Laborato.. |
Motilal Oswal
|
5609.35 | 5240.00 | 5507.00 (1.86%) | -6.58 |
Neutral
|
||||
27 Jul 2023 | Dr. Reddy's Laborato.. |
SMC online
|
5609.35 | 5507.00 (1.86%) |
Results Update
|
||||||
27 Jul 2023 | Dr. Reddy's Laborato.. |
ICICI Securities Limited
|
5609.35 | 6000.00 | 5475.65 (2.44%) | 6.96 |
Accumulate
|
Better volumes in US drives margins
ICICI Securities Limited
Dr. Reddy’s (DRL) delivered a strong beat in EBITDA and profit, driven by incremental sales from its base product portfolio and gRevlimid in the US. gRevlimid continues to lift overall margins; however, additional sales from products that are in shortage in the US improved base business margins in Q1FY24.
|
|||
27 Jul 2023 | Dr. Reddy's Laborato.. |
Axis Direct
|
5609.35 | 6000.00 | 5507.00 (1.86%) | 6.96 |
Hold
|
||||
27 Jul 2023 | Dr. Reddy's Laborato.. |
Prabhudas Lilladhar
|
5609.35 | 5150.00 | 5507.00 (1.86%) | 8.19 |
Sell
|
||||
04 Jul 2023 | Dr. Reddy's Laborato.. |
Sharekhan
|
5609.35 | 5963.00 | 5178.35 (8.32%) | Target met |
Buy
|
||||
23 Jun 2023 | Dr. Reddy's Laborato.. |
Motilal Oswal
|
5609.35 | 4680.00 | 4993.90 (12.32%) | -16.57 |
Neutral
|
||||
12 May 2023 | Dr. Reddy's Laborato.. |
KRChoksey
|
5609.35 | 5155.00 | 4466.10 (25.60%) | Target met |
Buy
|
Lower volume growth in gRevlimid impacted the margin
KRChoksey
DRReddy’s saw a sequential drop in revenue to INR 63,152 Mn. Global generics, reported a revenue of INR 54,257 Mn, declined by 8% on a QoQ. However, the company witnessed YoY growth of 23.4%, driven by revenue growth in North America, Europe and India, partially offset by a decline of revenues in the emerging markets.
|
|||
11 May 2023 | Dr. Reddy's Laborato.. |
SMC online
|
5609.35 | 4532.00 (23.77%) |
Results Update
|
||||||
11 May 2023 | Dr. Reddy's Laborato.. |
BOB Capital Markets Ltd.
|
5609.35 | 4900.00 | 4532.00 (23.77%) | Target met |
Hold
|
||||
11 May 2023 | Dr. Reddy's Laborato.. |
ICICI Direct
|
5609.35 | 5520.00 | 4532.00 (23.77%) | Target met |
Buy
|
||||
11 May 2023 | Dr. Reddy's Laborato.. |
Motilal Oswal
|
5609.35 | 4500.00 | 4532.00 (23.77%) | Target met |
Neutral
|
||||
11 May 2023 | Dr. Reddy's Laborato.. |
Axis Direct
|
5609.35 | 5100.00 | 4532.00 (23.77%) | Target met |
Hold
|
||||
11 May 2023 | Dr. Reddy's Laborato.. |
Prabhudas Lilladhar
|
5609.35 | 4500.00 | 4532.00 (23.77%) | Target met |
Sell
|
||||
07 Feb 2023 | Dr. Reddy's Laborato.. |
Geojit BNP Paribas
|
5609.35 | 5166.00 | 4440.25 (26.33%) | Target met |
Buy
|
||||
27 Jan 2023 | Dr. Reddy's Laborato.. |
Axis Direct
|
5609.35 | 5100.00 | 4314.00 (30.03%) | Target met |
Buy
|
||||
27 Jan 2023 | Dr. Reddy's Laborato.. |
ICICI Direct
|
5609.35 | 5210.00 | 4314.00 (30.03%) | Target met |
Buy
|
||||
27 Jan 2023 | Dr. Reddy's Laborato.. |
ICICI Securities Limited
|
5609.35 | 5131.00 | 4200.95 (33.53%) | Target met |
Buy
|
Revlimid springs a surprise, again!
ICICI Securities Limited
Dr. Reddy’s Laboratories’ (DRL) Q3FY23 reported performance exceeded our and consensus estimates, largely driven by higher-than-estimated sales of Revlimid in Q3FY23. This resulted in 27.3% YoY growth in revenue to Rs67.7bn (I-Sec: Rs58.6bn).
|
|||
more
loading
|